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Sermorelin: A better approach to management of adult-onset growth 
hormone insufﬁ  ciency?
Growth hormone replacement therapy (GHRT) using recombinant human growth 
hormone (rhGH) has been embraced by many age management practitioners as one 
of the most effective methods for opposing somatic senescence currently available. 
However, its routine use has been controversial because few clinical studies have been 
performed to determine the potential risks of long-term therapy. Also, certain medical 
and legal issues have not been resolved causing some practitioners to restrict their use 
of the product. Some of these issues include the fact that:
•  Improper dosing can lead to side effects that may be serious in some patients,
•  Injection of hGH creates unnatural conditions of exposure to the hormone that 
may erode normal physiology,
•  The Code of Federal Regulations speciﬁ  cally forbids the use of rhGH in adults 
except for treatment of AIDS or human growth hormone deﬁ  ciency (GHD) 
diagnosed pursuant to regularly accepted guidelines.
While there is a wealth of information showing that long-term administration 
of rhGH reduces intrinsic disease and extends life in adults suffering pathogenic 
GHD, consensus on whether extrapolation of those data to the aging condition 
is justiﬁ  ed has not been reached (Perls et al 2005). Most of the major concerns 
derive from the fact that rhGH is mitogenic and may awaken latent cancers, that 
improper dose selection may promote metabolic disorders such as diabetes, and 
perhaps that pharmacological presentation may exacerbate decline of endocrine 
function by distorting essential hormonal interactions. Of course, all these concerns 
are speculative and will not be resolved until sufﬁ  cient scientiﬁ  c evidence for or 
against GHRT eventually accumulate. In the interim, the value of rhGH in GHRT 
will continue to be debated; unfortunately based more upon personal prejudice than 
objective information.
Despite the eventual outcome to the “Great Hormone Debate” as it has been 
titled in media articles (Landsmann 2006), certain negative aspects of GHRT using 
rhGH cannot be disputed and justify searching for a better alternative. For example, 
“square wave” or pharmacological presentation of the exogenous hormone cannot 
be avoided since it is administered as a bolus, subcutaneous injection. Since the 
amount of rhGH entering the general circulation is not controlled by normal feedback 
mechanisms, tissue exposure to elevated concentrations is persistent and eventually 
may lead to tachyphylaxis and reduced efﬁ  cacy. Also, because the body cannot 
modulate tissue exposure to rhGH, the practitioner is required to “best guess” the 
appropriate dosage based upon little other than serum measurements of insulin-like 
growth factor-1 (IGF-1) and subjective comments from the patient about perceived 
responses to the hormone. Thus, it would seem that an alternative method(s) of GHRT 
that circumvented these problems would be of great value so long as it retained the 
positive attributes of rhGH. 
One possibility that is receiving growing attention is the use of GH secretagogues 
to promote pituitary health and function during aging. An example of such molecules 
is growth hormone releasing factor 1-29 NH2-acetate, or sermorelin, that recently 
became available to practitioners for use in longevity medicine (Merriam et al 
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that are currently being developed by pharmaceutical 
companies. Some of these have been reported to be effective 
at improving physical performance in the elderly (Fahy 
2006). However, it is unlikely that they will be marketed 
for several years. On the other hand, sermorelin, an analog 
of naturally occurring growth hormone-releasing hormone 
(GHRH) whose activity declines during aging, may 
presently offer a more immediate and better alternative to 
rhGH for GHRT in aging (Russell-Aulet et al 2001). The 
molecule was commercially produced and marketed for 
many years as an alternative to rhGH for use in children 
with growth retardation, but it could not compete with 
rhGH and was withdrawn as a therapeutic entity by the 
manufacturer. Paradoxically sermorelin failed as a growth-
promoting agent in children for the very reason that it is 
a better alternative for GHRT in aging adults. Growth-
deﬁ  cient children need higher doses of growth hormone 
than can be achieved by stimulating production of their 
own hormone, whereas the beneﬁ  cial effects of sermorelin 
on pituitary function and simulation of youthful growth 
hormone secretory dynamics in aging adults have little 
effect on growth rate in children. Unlike exogenous rhGH 
that causes production of the bioactive hormone IGF-1 from 
the liver, sermorelin simulates the patients own pituitary 
gland by binding to speciﬁ  c receptors to increase production 
and secretion of endogenous hGH. Because sermorelin 
increases endogenous hGH by stimulating the pituitary 
gland, it has certain physiological and clinical advantages 
over hGH that include:
•  Effects are regulated by negative feedback involving 
the inhibitory neurohormone, somatostatin, so that 
unlike administration of exogenous rhGH, overdoses 
of endogenous hGH are difﬁ  cult if not impossible to 
achieve,
•  Because of the interactive effects of sermorelin and 
somatostain, release of hGH by the pituitary is episodic or 
intermittent rather than constant as with injected rhGH.
•  Tachphylaxis is avoided because sermorelin-induced 
release of pituitary hGH is not “square wave”, but instead 
simulates more normal physiology, 
•  Sermorelin stimulates pituitary gene transcription of 
hGH messenger RNA, increasing pituitary reserve 
and thereby preserving more of the growth hormone 
neuroendocrine axis, which is the ﬁ  rst to fail during 
aging (Walker et al 1994). 
•  Pituitary recrudescence resulting from sermorelin helps 
slow the cascade of hypophyseal hormone failure that 
occurs during aging thereby preserving not only youthful 
anatomy but also youthful physiology (Villalobos et al 
1997).
Finally, there is the question of lawful practice. Unlike 
rhGH which has legal restrictions on its clinical use, the 
off-label prescribing of sermorelin is not prohibited by 
federal law. Thus, it can be carefully employed and evaluated 
by the practitioner to objectively determine whether it 
provides greater beneﬁ  ts with less risk to his/her patients. 
In support of this effort, the Society for Applied Research 
in Aging will be providing sermorelin free of cost on a 
competitive basis to practitioners willing to study its effects 
under protocol conditions and to report the outcomes in 
a peer-reviewed journal such as Clinical Interventions in 
Aging. Hopefully, through such efforts we can contribute 
to development of a paradigm for evidence-based GHRT in 
clinical age management. 
For more information on this effort and to participate in 
the protocol, please contact sermorelin@dovepress.com. 
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